Compiled by the editorial desk with reference to official press releases and previous peer-reviewed publications.

In a three-year clinical trial, the injectable medication tirzepatide—marketed by Eli Lilly as Mounjaro for diabetes and Zepbound for weight loss—reduced the likelihood of progression to type 2 diabetes by 94% among adults with prediabetes who were overweight or obese. The findings, released by the company, also showed that the protective effect largely persisted even after participants stopped taking the drug.

The results come from the SURMOUNT-1 trial, a phase 3 study that followed 1,032 participants with elevated blood sugar levels—a condition known as prediabetes—for 176 weeks. During that period, subjects received either weekly injections of tirzepatide or a placebo. After the treatment phase, a 17-week washout period was observed, during which no medication was administered. According to the company's statistical analysis, the risk reduction at the end of the treatment phase was between 93% and 94%. After the washout, the reduction remained high at 88%.

Prediabetes, defined as blood sugar levels higher than normal but not yet meeting the threshold for diabetes, is a major risk factor for developing type 2 diabetes. Lifestyle changes, including diet and exercise, are traditionally recommended as first-line prevention. The new data, however, suggest that pharmacological intervention may offer substantial benefit.

In addition to the diabetes risk reduction, participants taking tirzepatide experienced an average weight loss of nearly 23% over the three-year period. This weight reduction is believed to be a contributing factor to the lowered diabetes risk, though the exact mechanism remains under investigation.

The trial also documented side effects consistent with the class of drugs known as GLP-1 receptor agonists, which include gastrointestinal issues. Lilly advises that individuals considering tirzepatide should consult their healthcare providers about these potential adverse effects. The company also noted that oral contraceptives may be less effective when taken alongside tirzepatide, a finding that has implications for women of reproductive age.

These results have not yet undergone peer review. However, a primary analysis from the first 72 weeks of the SURMOUNT-1 trial was published in the New England Journal of Medicine in 2022.

Why This Matters

The findings are part of a broader wave of research into GLP-1-type medications, which have gained widespread attention for their effectiveness in weight management and potential metabolic benefits. The trial is notable for its duration, being the longest to date for this class of drugs. However, the commercial success of these medications, which have generated billions in revenue for manufacturers, underscores the need for careful interpretation of the data.

As with any emerging therapy, the long-term implications and optimal use of tirzepatide for diabetes prevention will require further study and regulatory review. The current results, while promising, are preliminary and await validation by the scientific community.